News and Views
Nature Chemical Biology 5, 274 - 275 (2009)
doi:10.1038/nchembio0509-274
Fragment-based drug discovery takes a virtual turn
Maurizio Pellecchia1
- Maurizio Pellecchia is a professor of Medicinal Chemistry and Structural Biology in the Cancer Center and Infectious Diseases Center of the Burnham Institute for Medical Research, La Jolla, California, USA. e-mail: mpellecchia@burnham.org
Abstract
In the realm of modern drug discovery technologies, fragment-based approaches and virtual ligand screening are emerging alternative approaches to high-throughput screening (HTS). For as simple as it sounds, a hybrid approach in which fragments are discovered first in silico may be an unbeatable route to hit identification for some drug targets.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A new school for screeningNature Biotechnology News and Views (01 Feb 2005)
Puzzling through fragment-based drug designNature Chemical Biology News and Views (01 Dec 2006)
RESEARCH
Molecular docking and ligand specificity in fragment-based inhibitor discoveryNature Chemical Biology Article (01 May 2009)
